Advertisement

19 Geneesmiddelen, speeksel en speekselklieren

Chapter
  • 831 Downloads

Samenvatting

  • De bijwerking die sommige geneesmiddelen uitoefenen op de speekselklieren kan geheel verschillend van aard zijn: de secretiesnelheid kan zijn verlaagd of verhoogd, de klieren zelf kunnen in omvang toenemen, de eiwitbiosynthese kan kwalitatief en kwantitatief veranderen. Tevens kunnen pijngewaarwording in de speekselklieren, smaakveranderingen en halitose optreden.

  • Bij psychiatrische patiënten is de speekselreductie veelal gerelateerd aan het gebruik van antidepressiva, vooral de wat oudere soorten. De apathie en de slechte orale gezondheid, gecombineerd met de medicatiegeïnduceerde xerostomie, maken deze patiënten tot een hoogrisicogroep voor het ontwikkelen van orale ontstekingen en tandbederf.

  • De droge mond bij ouderen is in het merendeel van de gevallen te wijten aan de bijwerking van de medicatie (zie hoofdstuk 18).

  • Chronische toediening van pilocarpine aan patiënten met speekselklierdisfunctie geeft een verhoging van de speekselsecretie zonder opvallende bijverschijnselen. In voorkomende gevallen kan dit een effectief therapeuticum zijn als men met gustatoire sialagoga niet uitkomt.

  • Toediening van isoproterenol voor de verhoging van de speekselsecretie resulteert in vergroting van de speekselklieren en kan de samenstelling van speeksel zowel kwalitatief als kwantitatief veranderen.

  • Smaakveranderingen die optreden door het gebruik van onder andere cytostatica verlagen dikwijls de eetlust, wat de lichamelijke weerstand niet ten goede komt.

Literatuur

  1. Abdollahi M., B. Minaiee en A.A. Yaaghoubi. Structural and functional changes byciprofloxacin of rat submandibular gland. Hum. Exptl Toxicol. 22, (2003)177–181.CrossRefGoogle Scholar
  2. Acosta-Armas A.J. Two cases of parotid gland swelling in patients taking clozapine. Hosp. Med. 62, (2001)704–705.PubMedGoogle Scholar
  3. Adachi K., M. Ono, A. Kawamura, M. Yuki, H. Fujishiro en Y. Kinoshita. Nizatidine and cisapride enhance salivary secretion in humans. Aliment. Pharmacol. Ther. 16, (2002)297–301.PubMedCrossRefGoogle Scholar
  4. Ariëns E.J., G. Boering en D.K.F. Meijer. Het Geneesmiddel in de tandheelkunde. De Nederlandse Bibliotheek der Tandheelkunde, deel 5. Samsom Stafleu, Alphen aan den Rijn, 1984.Google Scholar
  5. Bagheri H., L. Schmidt, M. Berlan en J.L. Montrastrui. A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs. Eur. J. Clin. Pharmacol. 52, (1997)339–342.PubMedCrossRefGoogle Scholar
  6. Bai Y.-M., C.-C. Lin, J.-Y. Chen en W.C. Liu. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: A randomized, double-blind, placebo-controlled, cross-over study. J. Clin. Psychopharm. 21, (2001)608–611.CrossRefGoogle Scholar
  7. Batra S. en A. Biörklund. Binding affinities of four tricyclic antidepressive drugs to muscarinic cholinergic receptors in human parotid gland. Psychopharm. 90, (1986)1–4.CrossRefGoogle Scholar
  8. Beers E. en A.C. van Grootheest. Bruxisme als bijwerking van serotonineheropnameremmers. Ned. Tijdschr. Tandheelkd. 114, (2007)388–390.PubMedGoogle Scholar
  9. Bergdahl M. en J. Bergdahl. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J. Dent. Res. 79, (2000)1652–1658.PubMedCrossRefGoogle Scholar
  10. Berteretche M.V., A.M. Dalix, A.M. Cesar d’Ornano, F. Bellisle, D. Khayat en A. Faurion. Decreased taste sensitivity in cancer patients under chemotherapy. Supp. Care Cancer 12, (2004)571–576.CrossRefGoogle Scholar
  11. Bymaster F.P., P.A. Carter, M. Yamada, J. Gomeza, J. Wess, S.E. Hamilton, e.a. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur. J. Neuroscience 17, (2003)1403–1410.CrossRefGoogle Scholar
  12. Cetkovsky P. en V. Koza. Salivary glands enlargement in association with cytosine arabinoside application in patients with acute myeloid leukaemia. Eur. J. Cancer 30A, (1994)1727–1728.PubMedCrossRefGoogle Scholar
  13. Chae H.-J., M.-S. Ha, D.-H. Yun, H.-O. Pae, H.-T. Chung, S.-W. Chae, e.a. Mechanism of cyclosporine-induced overgrowth in gingiva. J. Dent. Res. 85, (2006)515–519.PubMedCrossRefGoogle Scholar
  14. Cheng K.K.F. Oral mucositis, dysfunction, and distress in patients undergoing cancer therapy. J. Clin. Nursing 16, (2007)2114–2121.CrossRefGoogle Scholar
  15. Chin Y.-T., Y.-T. Chen, H.-P. Tu, E.-C. Shen, C.Y. Chiang, C.-H. Gau, e.a. Upregulation of the expression of epidermal growth factor and its receptor in gingiva upon cyclosporin A treatment. J. Periodontol. 77, (2006)647–656.PubMedCrossRefGoogle Scholar
  16. Choi S.-Y., J. Li, S.-H. Jo, S.J. Lee, S.B. Oh, J.-S. Kim, e.a. Desipramine inhibits Na+/ H+ exchanger in human submandibular cells. J. Dent. Res. 85, (2006)839–843.PubMedCrossRefGoogle Scholar
  17. Ciancio S.G. Medications as risk factors for periodontal disease. J. Periodont. 67, (1996)1055–1059.PubMedCrossRefGoogle Scholar
  18. Das S.J., H.N. Newman en I. Olsen. Keratinocyte growth factor receptor is up-regulated in cyclosporin A-induced gingival hyperplasia. J. Dent. Res. 81, (2002)683–687.PubMedCrossRefGoogle Scholar
  19. Ehlert U., K. Erni, G. Hebisch en U. Nater. Salivary a-amylase levels after yohimbine challenge in healthy men. J. Clin. Endocrin. Metabol. 91, (2006)5130–5133.CrossRefGoogle Scholar
  20. Elad S., S. Heisler en M. Shalit. Saliva secretion in patients with allergic rhinitis. Allergy Immunol. 141, (2006)276–280.CrossRefGoogle Scholar
  21. Fife R.S., W.F. Chase, R.K. Dore, C.W. Wiesenhutter, P.B. Lockhart, E. Tindall, e.a. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome – a randomized trial. Arch. Intern. Med. 162, (2002)1293–1300.PubMedCrossRefGoogle Scholar
  22. Forsthöfel S., A.S.H. Duinkerke en J.A.J. Trip. Een gezondheidsvragenlijst bij het maken van een volledige gebitsprothese. Ned. Tijdschr. Tandheelkd. 94 (1987)359–368.PubMedGoogle Scholar
  23. Fox P.C. Systemic therapy of salivary gland hypofunction. J. Dent. Res. 66, (1987)689–692.PubMedGoogle Scholar
  24. Fox P.C., P.F. van der Ven, B.J. Baum en I.D. Mandel. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg. Oral Med. Oral Pathol. 61, (1986)243–245.PubMedCrossRefGoogle Scholar
  25. Goldin G.F., M. Marcinkiewicz, T. Zbroch, L.P. Bityutskiy, R.W. McCallum en J. Sarosiek. Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease. Dig. Dis. Sci. 42, (1997)1362–1369.PubMedCrossRefGoogle Scholar
  26. Ghezzi E.M. en J.A. Ship. Systemic diseases and their treatments in the elderly: impact on oral health. J. Public Health Dent. 60, (2000)289–296.PubMedCrossRefGoogle Scholar
  27. Güncü G.N., F. Caglayan, A. Dincel, A. Bozkurt, S. Saygi en E. Karabulut. Plasma and gingival crevicular fluid phenytoin concentrations as risk factors for gingival overgrowth. J. Periodontol. 77, (2006)2005–2010.PubMedCrossRefGoogle Scholar
  28. Hamada T., T. Nakane, T. Kimura, K. Arisawa, K. Yoneda, T. Yamamoto, e.a. Treatment of xerostomia with the bile secretion stimulating drug anetholetrithione: a clinical trial. Am. J. Med. Sci. 318, (1999)146–151.PubMedCrossRefGoogle Scholar
  29. Hedner E., D. Birkhed, J. Hedner, J. Ekström en H.F. Helander. Stimulation of minor salivary glands by intraoral treatment with the cholinesterase inhibitorphysostigmine in man. Eur. J. Oral Sci. 109, (2001)371–374.PubMedCrossRefGoogle Scholar
  30. Hoffmann J. en G. Schwoch. Co-ordinated changes in the cyclic AMP signalling system and the phosphorylation of two nuclear proteins of Mr 130,000 and 110,000 during proliferative stimulation of the rat parotid gland by isoprenaline. Possible identity of the two proteins with pp135 and nucleolin. Biochem. J. 263, (1989)785–793.PubMedCentralPubMedGoogle Scholar
  31. Hunter K.D. en W.S. Wilson. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Archs Oral Biol. 40, (1995)983–989.CrossRefGoogle Scholar
  32. Ikeda K., S. Kobayashi, M. Suzuki, K. Miyata, M. Takeuchi, T. Yamada, e.a. M3 receptor antagonism by the novel anti-muscarinic agent solifenacin inthe urinary bladder and salivary gland. Archs Pharmacol. 366, (2002)97–103.CrossRefGoogle Scholar
  33. Iseki S., J.-G. Kim, Y. Kudo, Y. Naito en W. Hipkaeo. Impaired induction of cystatin S gene expression by isoproterenol in submandibular gland of hypophysectomized rats. Archs Oral Biol. 50, (2005)653–660.CrossRefGoogle Scholar
  34. Knorring L. von en H. Mörnstad. Saliva secretion rate and saliva composition as a model to determine the effect of antidepressant drugs on cholinergic and noradrenergic transmission. Neuropsychobiol. 15 (1986)146–154.CrossRefGoogle Scholar
  35. Knorring A-L. von en Y-B. Wahlin. Tricyclic antidepressants and dental caries in children. Neuropsychobiol. 15, (1986)143–145.CrossRefGoogle Scholar
  36. Koller M.M., N. Maeda, P.J. Scarpace en M.G. Humphreys-Beher. Desipraminechanges salivary gland function, oral microbiota, and oral health in rats. Eur. J.Pharm. 408, (2000)91–98.CrossRefGoogle Scholar
  37. Koller M.M., R.A. Cowman, M.G. Humphreys-Beher en P.J. Scarpace. An analysis of submandibular gland function with desipramine and age in female NIA Fischer 344 rats. Mech. Ageing Dev. 119,(2000)131–147.PubMedCrossRefGoogle Scholar
  38. Kujirai M., K. Sawaki en M. Kawaguchi. Inhibitory effect of diazepam on muscarinic receptor-stimulated inositol 1,4,5-trisphosphate production in rat parotid acinar cells. Br. J. Pharmacol. 137, (2002)945–952.PubMedCentralPubMedCrossRefGoogle Scholar
  39. Kuru L., S. Yilmaz, B. Kuru, K.N. Köse en U. Noyan. Expression of growth factors in the gingival crevice fluid of patients with phenytoin-induced gingival enlargement. Archs Oral Biol. 49, (2004)945–950.CrossRefGoogle Scholar
  40. Lu H.-K., H.-P. Chou, C.-L. Li, M.-Y. Wang en L.-F. Wang. Stimulation of cells derived from nifedipine-induced gingival overgrowth with Porphyromonas gingivalis, lipopolysaccharide, end interleukine-1β. J. Dent. Res. 86, (2007)1100–1104.PubMedCrossRefGoogle Scholar
  41. Markopoulos A.K., M. Belazi, D. Drakoulakos, C. Petrou-Americanou, A. Sioulis, D. Sakellari, e.a. EGF in saliva and serum of patients with cyclosporine-induced gingival overgrowth. J. Periodont. Res. 36, (2001)88–91.PubMedCrossRefGoogle Scholar
  42. Marshall R.I. en P.M. Bartold. Medication induced gingival overgrowth. Oral Dis. 4, (1998)130–151.PubMedCrossRefGoogle Scholar
  43. Mörnstad H., L. von Knorring, L. Forsgren en S. Holmgren. Acute effects of some different antide- pressant drugs on saliva composition. Neuropsychobiol. 15, (1986)73–79.CrossRefGoogle Scholar
  44. Nieuw Amerongen A. van. Astmapatiënten: orale gevolgen van adrenerge agonisten. Ned. Tijdschr. Tandheelkd. 95, (1988)52–54.PubMedGoogle Scholar
  45. Nieuw Amerongen A. van. Speekselveranderingen door medicijngebruik. Ned.Tijdschr. Tandheelkd. 97, (1990)382–385.PubMedGoogle Scholar
  46. Ochiai S., S. Hashimoto en M. Shimono. Acinar cell hypertrophy, proliferation and cell death in rat submandibular glands induced by long-term isoproterenol administration. Acta Histochem. Cytochem. 35, (2002)383–393.CrossRefGoogle Scholar
  47. Patel R., J. Launspach en E. Soffer. Effects of cisapride on salivary production in normal subjects. Dig. Dis. Sci. 41, (1996)480–484.PubMedCrossRefGoogle Scholar
  48. Peeters F.P.M.L., M.W. de Vries en A. Vissink. Risks for oral health with the use of antidepressants. Gen. Hosp. Psychiatry 20, (1998)150–154.PubMedCrossRefGoogle Scholar
  49. Petrone D., J.J. Condemi, R. Fife, O. Gluck, S. Cohen en P. Dalgin. A double-blind, randomized, placebocontrolled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 46, (2002)748–754.PubMedCrossRefGoogle Scholar
  50. Popovic J., E. Krsljak, L. Grbovic en D. Stojic. The effects of acute and chronic lithium treatment on rat submandibular salivation. Oral Dis. 11, (2005)100–103.PubMedCrossRefGoogle Scholar
  51. Rees T.D. Drugs and oral disorders. Periodontology 2000 18, (1998)21–36.CrossRefGoogle Scholar
  52. Renner U.D., R. Oertel en W. Kirch. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Drug. Monit. 27, (2005)655–665.CrossRefGoogle Scholar
  53. Rode M., L. Smid, M. Budjihna, D. Gaspersic, M. Rode en E. Soba. The influence of pilocarpine and biperiden on pH value and calcium, phosphate, and bicarbonate concentrations in saliva during and after therapy for head and neck cancer. Oral Surg. Oral Med. Oral Pathol., Oral Radiol. Endodontol. 92, (2001)509–514.CrossRefGoogle Scholar
  54. Rundegren J., J. van Dijken, H. Mörnstad en L. von Knorring. Oral conditions in patients receiving long-term treatment with cyclic antidepressant drugs. Swed. Dent. J. 9, (1985)55–64.PubMedGoogle Scholar
  55. Schubert M.M. en K.T. Izutsu. Iatrogenic causes of salivary gland dysfunction. J. Dent. Res. 66, (1987)680–688.PubMedGoogle Scholar
  56. Solis R.L., M.P. Diaz, I.M. Bozo, U.K. Weis en F. Diaz. Early detection in saliva of polypeptides associated to isoproterenol-induced mouse parotid hypertrophy. Biochim. Biophys. Acta – General Subjects 1621, (2003)41–47.CrossRefGoogle Scholar
  57. Spiller J.A. en M. Fallon. The use of scopoderm in palliative care. Hosp. Med. 61, (2000)782–784.PubMedCrossRefGoogle Scholar
  58. Spolidorio L.C., M. Holzhausen, D.M. Palomari Spolidorio, C.A. Nassar, P.O. Nassar en M.N. Muscara. Cyclosporin but not tacrolimus significantly increases salivary cytokine contents in rats. J. Periodontol. 76, (2005)1520–152.PubMedCrossRefGoogle Scholar
  59. Spratt H., S. Boomer, C.R. Irwin, J.J. Marley, J.A. James, P. Maxwell, e.a. Cyclosporin associated gingival overgrowth in renal transplants recipients. Oral Dis. 5, (1999)27–31.PubMedCrossRefGoogle Scholar
  60. Thomaz Takakura A.C., T. dos Santos Moreira, L.A. De Luca, A. Renzi en J. Vanderlei Menani. Central α2-adrenergic receptors and cholinergic-induced salivation in rats. Brain Res. Bull. 59, (2003)383–386.Google Scholar
  61. Tredwin C.J., C. Scully en J.-V. Bagan-Sebastian. Drug-induced disorders of teeth. J. Dent. Res. 84, (2005)596–602.PubMedCrossRefGoogle Scholar
  62. Trip J.A.J. Effecten van geneesmiddelen op het tandheelkundig handelen. Ned. Tijdschr. Tandheelkd. 92, (1985)404–407.PubMedGoogle Scholar
  63. Vissink A., A. van Nieuw Amerongen, H. Wesseling en E.J. ’s-Gravenmade. De droge mond. De mogelijk oorzakelijke rol van geneesmiddelen. Ned. Tijdschr. Tandheelkd. 99, (1992)103–112.PubMedGoogle Scholar
  64. Vissink A., A. van Nieuw Amerongen en E.Th.H.G.J. Oremus. De invloed van geneesmiddelen op het orofaciale gebied. Ned. Tijdschr. Tandheelkd. 106, (1999)254–263.PubMedGoogle Scholar
  65. Vissink A., R. van Weissenbruch en A. van Nieuw Amerongen. Smaak- en reukstoornissen. Ned. Tijdschr. Tandheelkd. 108, (2001)229–236.PubMedGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum, onderdeel van Springer Uitgeverij 2008

Authors and Affiliations

  1. 1.Sectie Orale BiochemieAcademisch Centrum Tandheelkunde Amsterdam (ACTA), Vrije Universiteit en Universiteit van AmsterdamAmsterdam

Personalised recommendations